High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients.


Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
06 2022
Historique:
received: 08 10 2021
revised: 28 02 2022
accepted: 08 03 2022
entrez: 23 5 2022
pubmed: 24 5 2022
medline: 26 5 2022
Statut: ppublish

Résumé

Serological responses to COVID-19 vaccination are diminished in recipients of solid organ transplants, especially in lung transplant recipients (LTR), probably as result of immunosuppressive treatment. There is currently no marker of immunosuppression that can be used to predict the COVID-19 vaccination response. Here, we study whether torque tenovirus (TTV), a highly prevalent virus can be used as an indicator of immunosuppression. The humoral response to the mRNA 1273 vaccine was assessed in 103 LTR, who received a transplant between 4 and 237 months prior to vaccination, by measuring Spike (S)-specific IgG levels at baseline, 28 days after first, and 28 days after the second vaccination. TTV loads were determined by RT-PCR and Pearson's correlation coefficient was calculated to correlate serological responses to TTV load. Humoral responses to COVID-19 vaccination were observed in 41 of 103 (40%) LTR at 28 days after the second vaccination. Sixty-two of 103 (60%) were non-responders. Lower TTV loads at baseline (significantly) correlated with higher S-specific antibodies and a higher percentage of responders. Lower TTV loads also strongly correlated with longer time since transplantation, indicating that participants with lower TTV loads were longer after transplantation. This study shows a better humoral response to the SARS-CoV-2 vaccine in subjects with a lower TTV load pre-vaccination. In addition, TTV load correlates with the time after transplantation. Further studies on the use of TTV load in vaccination efficacy studies in immunocompromised cohorts should provide leads for the potential use of this marker for optimizing vaccination response.

Sections du résumé

BACKGROUND
Serological responses to COVID-19 vaccination are diminished in recipients of solid organ transplants, especially in lung transplant recipients (LTR), probably as result of immunosuppressive treatment. There is currently no marker of immunosuppression that can be used to predict the COVID-19 vaccination response. Here, we study whether torque tenovirus (TTV), a highly prevalent virus can be used as an indicator of immunosuppression.
METHODS
The humoral response to the mRNA 1273 vaccine was assessed in 103 LTR, who received a transplant between 4 and 237 months prior to vaccination, by measuring Spike (S)-specific IgG levels at baseline, 28 days after first, and 28 days after the second vaccination. TTV loads were determined by RT-PCR and Pearson's correlation coefficient was calculated to correlate serological responses to TTV load.
RESULTS
Humoral responses to COVID-19 vaccination were observed in 41 of 103 (40%) LTR at 28 days after the second vaccination. Sixty-two of 103 (60%) were non-responders. Lower TTV loads at baseline (significantly) correlated with higher S-specific antibodies and a higher percentage of responders. Lower TTV loads also strongly correlated with longer time since transplantation, indicating that participants with lower TTV loads were longer after transplantation.
CONCLUSIONS
This study shows a better humoral response to the SARS-CoV-2 vaccine in subjects with a lower TTV load pre-vaccination. In addition, TTV load correlates with the time after transplantation. Further studies on the use of TTV load in vaccination efficacy studies in immunocompromised cohorts should provide leads for the potential use of this marker for optimizing vaccination response.

Identifiants

pubmed: 35606065
pii: S1053-2498(22)01854-X
doi: 10.1016/j.healun.2022.03.006
pmc: PMC8924026
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
2019-nCoV Vaccine mRNA-1273 EPK39PL4R4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

765-772

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Références

J Clin Virol. 2010 Feb;47(2):189-92
pubmed: 20034850
J Clin Virol. 2021 Jul;140:104871
pubmed: 34089977
Clin Microbiol Infect. 2016 Jul;22(7):589-93
pubmed: 27093875
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Transpl Int. 2020 Sep;33(9):1099-1105
pubmed: 32460390
J Infect. 2019 Jul;79(1):56-60
pubmed: 31100359
Eur Respir J. 2020 May 27;55(5):
pubmed: 32312863
Transpl Infect Dis. 2020 Dec;22(6):e13364
pubmed: 32521074
Rev Med Virol. 2010 Nov;20(6):392-407
pubmed: 20925048
J Clin Med. 2020 Feb 06;9(2):
pubmed: 32041187
Vaccines (Basel). 2021 Jun 30;9(7):
pubmed: 34208884
Clin Res Cardiol. 2021 Aug;110(8):1142-1149
pubmed: 34241676
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Biol Blood Marrow Transplant. 2018 Jan;24(1):194-199
pubmed: 29032273
PLoS One. 2015 Apr 20;10(3):e0122975
pubmed: 25894323
J Infect Dis. 2018 Sep 8;218(8):1191-1199
pubmed: 30007341
Transplantation. 2022 Apr 1;106(4):821-834
pubmed: 34753894
J Clin Virol. 2018 Aug;105:118-127
pubmed: 29957546
Clin Infect Dis. 2021 Dec 6;73(11):e4090-e4099
pubmed: 32766815
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Am J Transplant. 2020 Oct;20(10):2876-2882
pubmed: 32412159
HIV Clin Trials. 2002 Jul-Aug;3(4):287-95
pubmed: 12187502
J Heart Lung Transplant. 2021 Dec;40(12):1579-1588
pubmed: 34456108
Am J Transplant. 2021 Aug;21(8):2774-2784
pubmed: 34008917
Am J Transplant. 2021 May;21(5):1825-1837
pubmed: 33098200
J Heart Lung Transplant. 2021 Aug;40(8):754-758
pubmed: 34120839
J Heart Lung Transplant. 2014 Mar;33(3):320-3
pubmed: 24559947
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
Sci Rep. 2018 Oct 19;8(1):15490
pubmed: 30341363
Transplantation. 2021 Jan 1;105(1):177-186
pubmed: 33141808
J Infect Dis. 2000 May;181(5):1796-9
pubmed: 10823787

Auteurs

Rogier As Hoek (RA)

Department of Pulmonary Medicine, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Erik Am Verschuuren (EA)

Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, the Netherlands.

Rory D de Vries (RD)

Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.

Judith M Vonk (JM)

Department of Epidemiology and Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Debbie van Baarle (D)

Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, the Netherlands; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.

Marieke van der Heiden (M)

Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, the Netherlands.

Johanna P van Gemert (JP)

Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, the Netherlands.

Edmund J Gore (EJ)

Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, the Netherlands.

Hubert Gm Niesters (HG)

Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, the Netherlands.

Michiel Erasmus (M)

Department of Thoracic Surgery, University of Groningen, University Medical Center Groningen, Netherlands.

Merel E Hellemons (ME)

Department of Pulmonary Medicine, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Sandra Mj Scherbeijn (SM)

Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.

Nynke Wijbenga (N)

Department of Pulmonary Medicine, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Edris A F Mahtab (EAF)

Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands.

Corine H GeurtsvanKessel (CH)

Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.

Coretta Van Leer Buter (CVL)

Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, the Netherlands. Electronic address: c.van.leer@umcg.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH